On June 25th, OBIO organized a workshop with two industry leaders and provided a VC perspective on how they valuate start-up companies and on how this is translated into a deal structure, featuring presentations by Richard Meadows (General Partner, BioInnovation Capital Fund & OBIO Board Director) and Andy Haigh (COO, Adapsyn Bioscience).
On the evening of Tuesday, June 26th, David Cayea (COO, PlantForm Corporation) shared how PlantForm had developed a strategy for securing non-dilutive funding, through which they had raised over $6.5M in funding, via grants and research contracts alone.
On June 26th, OBIO hosted Building Your Early-Stage Strategy Toolbox featuring sessions on formulating a non-dilutive funding strategy, early-stage business strategies, and preparing investor materials.
On June 14th, OBIO hosted Dr. Yuan Fang (VP Regulatory Affairs, Quality and Manufacturing; Focal Healthcare Inc.) who spoke about his perspective on the recent changes at the U.S. Food and Drug Administration (FDA).
During his lively and highly engaging presentation on June 12, ‘Strategic Marketing & Commercialization Plans for Early Stage Companies,’ Dr. Brian Jahns (Senior VP, Commercial and Business Development at Trillium Therapeutics Inc) discussed approaches for developing strategies and the importance of scenario planning.
On May 10, 2018, Medical Device Playbook 2018 Toronto, co-hosted by Starfish Medical and OBIO, drew a standing-room only audience of 170 health science industry professionals, from company executives, to QA, regulatory and R&D engineering experts from start-ups, manufacturers, consultancies, regulatory and academic organizations.
On May 3, OBIO welcomed health science leaders, CEOs and the investment community to the tenth annual OBIO Leadership Event, also saw the launch of Use It or Lose It: Industry Solutions to Ontario's Commercialization Gap, OBIO's 2018 Industry Report.